{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-119242","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.225438+00:00","generated_at":"2026-05-16T13:56:10.162886+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protara Therapeutics prices public offering of 13M shares at $5.75 for $75M gross proceeds","bullets":["Priced 13,043,479 common shares at $5.75 per share; gross proceeds ~$75M before fees.","Underwriters granted 30-day option to buy up to 1,956,521 additional shares at same price.","Net proceeds to fund clinical development of TARA-002 and other pipeline programs.","Company and insiders subject to 60-day lock-up on share transfers post-offering.","Offering closed Dec 8, 2025; J.P. Morgan, TD Securities, Piper Sandler acted as representatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-119242","json":"https://secwatch.observer/filing/0001213900-25-119242.json","markdown":"https://secwatch.observer/filing/0001213900-25-119242.md","text":"https://secwatch.observer/filing/0001213900-25-119242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025119242/0001213900-25-119242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025119242/ea0268756-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:56:10.162886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"709fa87cac7286873218b0541f8feb8c1df52e71","claim":"Protara Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at approximately $75 million (effective 2025-12-04).","evidence_excerpt":"On December 4, 2025, Protara Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate of 13,043,479 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025119242/0001213900-25-119242-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters"},{"label":"Value","value":"approximately $75 million"},{"label":"Effective","value":"2025-12-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}